Skip to main content
Newron Pharmaceuticals S.p.A. logo

Newron Pharmaceuticals S.p.A. — Investor Relations & Filings

Ticker · NWRN ISIN · IT0004147952 LEI · 8156002F8C11F80A9740 SW Manufacturing
Open in API
Filings indexed 135 across all filing types
Latest filing 2025-01-09 M&A Activity
Country IT Italy
Listing SW NWRN

About Newron Pharmaceuticals S.p.A.

https://www.newron.com/

Newron Pharmaceuticals is a biopharmaceutical company focused on the research and development of novel therapies for diseases of the central and peripheral nervous system (CNS) and pain. The company's portfolio includes Xadago® (safinamide), a globally partnered treatment for Parkinson's disease. Its clinical-stage pipeline is centered on CNS disorders, with a key candidate, evenamide, under investigation for the treatment of schizophrenia.

Recent filings

Filing Released Lang Actions
EQS-News: Newron und Myung In Pharm geben Lizenzvereinbarung für Evenamide in Südkorea bekannt
M&A Activity Classification · 99% confidence The document is a press release announcing a licensing agreement between Newron Pharmaceuticals and Myung In Pharm regarding the drug Evenamide in South Korea. It details financial terms (upfront payment, milestones, royalties) and clinical development plans (Phase III study contribution). This type of announcement, detailing a significant business transaction, partnership, or licensing deal, is typically classified as a general corporate announcement or regulatory filing. Since there is no specific category for 'Licensing Agreement' or 'Business Development,' and it is not a formal financial report (10-K, IR, ER, MRQ), the most appropriate classification is the general regulatory filing/announcement category, RNS, as it is a material corporate event disclosed to the market via a news service (EQS-News). It is not a short announcement pointing to a separate report, as the core information is contained within the text itself, making RPA less likely than RNS for substantive news.
2025-01-09 German
EQS-Adhoc: Newron und EA Pharma (Tochtergesellschaft von Eisai Co., Ltd.) geben Lizenzvereinbarung für Evenamide in Japan und weiteren Regionen Asiens bekannt
Earnings Release Classification · 99% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and explicitly states it is 'Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014' (Publication of inside information according to Article 17 of Regulation (EU) No 596/2014). The content details a significant corporate event: a licensing agreement for a drug (Evenamide) between Newron and EA Pharma, including financial terms. This type of material, which is a mandatory disclosure of price-sensitive, non-public information under EU market abuse regulation (MAR), typically falls under general regulatory announcements or specific transaction/financing categories. Since it announces a major licensing deal and associated financial impact, it relates to corporate activity and potential financing/transaction elements. However, the primary nature is an immediate, mandatory disclosure of inside information. Given the options, this is a significant corporate event announcement. It is not a full 10-K, AR, ER, or IR. It is not a proxy statement (DEF 14A/PSI) or a management discussion (MDA). It is a regulatory filing announcing a major business development. The closest fit for a mandatory, non-standardized, price-sensitive announcement that isn't a routine earnings/dividend release is the general 'Regulatory Filings' (RNS) category, as it is an 'Ad hoc-Mitteilung' (Ad hoc announcement) mandated by EU regulation, which serves as a broad category for such disclosures when a more specific code (like TAR for M&A, or CAP for pure financing) doesn't perfectly capture the nature of a licensing agreement announcement. However, upon reviewing the definitions, this announcement details a major business transaction (licensing agreement) that involves significant future payments and rights transfer. While RNS is a fallback, the content strongly suggests a major corporate transaction/agreement. Since there is no specific 'Licensing Agreement' code, and it is not a merger (TAR), the most appropriate general regulatory disclosure category for mandatory, price-sensitive news that isn't routine financial reporting is RNS. If the document were shorter and only announced the *publication* of this information, RPA would apply, but this document contains the full substance of the inside information. FY 2024
2024-12-13 German
EQS-News: Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories
M&A Activity Classification · 99% confidence The document is a news release disseminated via EQS-News, announcing a significant business event: a license agreement between Newron Pharmaceuticals and EA Pharma regarding the drug evenamide in Asian territories. It details financial terms (€117 million potential value, €44 million upfront payment), development plans (Phase III trial in H1 2025), and includes commentary from CEOs. This type of announcement, focusing on a major corporate transaction (licensing/partnership) and its immediate financial impact, is best classified as a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were purely mandatory disclosure without the detailed business context. However, given the focus on securing significant funding/value through a licensing deal, 'CAP' is a strong fit, as it relates to capital structure/financing activities. Alternatively, since it is a broad corporate announcement of a material event, and 'CAP' is specifically for fundraising/financing activities, this licensing deal fits well under 'CAP' as it secures future revenue streams and development capital. If the focus was purely on the *result* of a vote or a general regulatory filing without specific content, RNS would be used. Since it details a major financial/strategic agreement, CAP is the most specific fit among the options that cover corporate actions, though it is also a type of news release. Given the structure and content, it is a material corporate announcement, but it is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a specific corporate action announcement. Since it involves a significant financial transaction (upfront payment and future milestones), 'CAP' (Capital/Financing Update) is the most appropriate classification over the general 'RNS'.
2024-12-13 English
EQS-News: Newron und EA Pharma (Tochtergesellschaft von Eisai Co., Ltd.) geben Lizenzvereinbarung für Evenamide in Japan und weiteren Regionen Asiens bekannt
M&A Activity Classification · 99% confidence The document is a press release announcing a licensing agreement between Newron Pharmaceuticals and EA Pharma regarding the drug Evenamide for specific Asian regions. It details financial terms (upfront payment, milestones, royalties), outlines future clinical trial plans (Phase III start in H1 2025), and provides background on the drug and the companies involved. This type of announcement, focusing on a significant business transaction (licensing/partnership) and its financial implications, is best classified as a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure without a specific category. However, since it details a major financing/deal structure (receiving EUR 117M), 'CAP' is a strong candidate. Given the context of major corporate transactions and fundraising activities, 'CAP' fits well. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a specific announcement, not just a notification that a report is available (RPA/RNS).
2024-12-13 German
EQS-Adhoc: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2024 und gibt ein Update zum Geschäftsverlauf
Earnings Release Classification · 100% confidence The document is titled 'Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2024 und gibt ein Update zum Geschäftsverlauf' (Newron publishes the results of the first half of 2024 and provides an update on business development). It explicitly states it is announcing 'Finanzergebnisse und operative Highlights für das am 30. Juni 2024 endende erste Halbjahr' (financial results and operational highlights for the first half ending June 30, 2024). It includes a detailed table of 'Finanzielle Kennzahlen (IFRS) H1 2024 und H1 2023' (Financial Figures H1 2024 and H1 2023). This content structure—comprehensive financial data and operational review for a period shorter than a year—is the definition of an Interim/Quarterly Report. The document is not merely an announcement of a report (RPA) because it contains the full financial details and narrative, despite being flagged as an 'Ad hoc-Mitteilung' (Ad hoc announcement), which often precedes or contains the full report for timely disclosure. H1 2024
2024-09-19 German
EQS-News: Newron presents H1 2024 results and provides business update
Earnings Release Classification · 100% confidence The document explicitly states it presents the 'H1 2024 results' and provides a 'Financial Summary (IFRS) H1 2024 and H1 2023'. The text details operational highlights, clinical trial updates, corporate financing activities, and financial performance for the half-year period ended June 30, 2024. This content aligns perfectly with the definition of a comprehensive financial report for a period shorter than a year, which corresponds to the Interim / Quarterly Report (IR) code. Although it mentions the 'Half-Report 2024 is available for download', the provided text *is* the content of that report, not just an announcement of its availability, given its substantial length and detailed financial tables. H1 2024
2024-09-19 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.